Prague (ots/PRNewswire) - Zentiva Group a.s. announces the completion of its previously declared acquisition of Romanian-based pharmaceutical company Solacium Pharma, together with its subsidiary, Be Well Pharma. The finalization of this acquisition will play a key role in the long-term growth strategy of Zentiva and will help to better support Romanian consumers' healthcare needs. About Zentiva Zentiva is a European ...
Not intended for media in the UK and the U.S. - Company launches global art campaign for people with MS to express their invisible symptoms and the unseen impact of the disease - Thought-provoking campaign coincides with the launch of MSonyourterms.com (http://www.msonmyterms.com/), a resource for patients, carers, and the public to understand MS from the Inside Out - Merck to donate EUR1 to the Multiple Sclerosis ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- , Canada- or US-based media ASCO Abstract # Bintrafusp alfa (bifunctional fusion protein): TPS9114; Tepotinib (MET kinase inhibitor): 9005; Discovery: 2567; ERBITUX® (cetuximab): 3580; BAVENCIO® (avelumab): 9569; 101; 4552; 4072 - New biomarker analyses ...
Duesseldorf, Germany (ots/PRNewswire) - Dr. Bernd Metzner (48) takes up the position of Chief Financial Officer of Gerresheimer AG on May 15, 2019. Dr. Metzner had been Chief Financial Officer of SDAX-listed Ströer SE & Co. KGaA since 2014. "I very much welcome the financial expertise and years of industry experience that Dr. Bernd Metzner brings to the Management ...
EUR62M funding will be used to progress wholly-owned pipeline products through clinical development and expand manufacturing activities Dr. Guido Guidi, Dr. Roberto Ferraresi and Dr. Roberto Marsella join the board of directors Siena, Italy (ots/PRNewswire) - Philogen S.p.A (or the "Company"), a clinical-stage biotechnology company focused on antibody-based therapeutics, today is pleased to announce a EUR62 million ...
Not intended for U.S. media - 48-week results provide additional evidence of relapse reduction for investigational evobrutinib - Evobrutinib demonstrated rapid lesion reductions on MRI at week 12 that were maintained through week 48, with no new safety signals identified over 52 weeks - Data presented at the ...
Not intended for U.S. or U.K. based media - 20 abstracts will be presented during the AAN Annual Meeting 2019 to demonstrate Merck's commitment and clinical development program in multiple sclerosis Darmstadt, Germany (ots/PRNewswire) - Merck, a leading science and technology company, today announced that data from ...
As part of its ongoing commitment to raising awareness of rosacea and the hidden burden of the disease, Galderma is collaborating with top social media influencers this Rosacea Awareness Month, to encourage people with rosacea to speak up and share experiences of the beyond the visible impact of living with this ...
- Rifaximin-a in combination with lactulose, the standard of care (SOC) treatment resulted in significant reductions ...
- Bempedoic acid is an oral, once-daily ATP citrate lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis in the liver - Bempedoic acid significantly reduced LDL-Cholesterol (LDL-C) vs placebo at week 12 (primary endpoint, absolute reduction -36mg/dL, -21,4%) - Over 24-weeks, bempedoic acid was ...
- MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment - MAVENCLAD's unique mechanism may provide an important new option for patients with ongoing active disease - MAVENCLAD demonstrated significant efficacy across key measures of disease activity ...
FOR EX-US MEDICAL AND TRADE MEDIA ONLY - T-cell prolymphocytic leukaemia is an extremely rare and aggressive T-cell leukaemia, with very limited effective treatment options1,2 - Tinostamustine is in very early phase clinical trials to investigate it as a potential future treatment option in this area of significant ...
FOR EUROPEAN MEDICAL AND TRADE MEDIA ONLY - Study will enrol 200 adult patients with limb trauma who are rescued by helicopter - Efficacy, tolerability and practicality of use of the inhaled analgesic in hostile mountain environments to be investigated Cambridge, England (ots/PRNewswire) - The Mundipharma network ...
EUR50,000 award goes to Newcastle University, in collaboration with Medical University, Graz and Newcastle Hospitals NHS Foundation Trust Staines-Upon-Thames, England (ots/PRNewswire) - Mallinckrodt plc (NYSE: MNK), a leading specialty pharmaceutical company, today announced the recipient of 2019's Advancing Extracorporeal Photopheresis (ECP) Immunomodulation ...
Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD® is now approved in 52 countries worldwide - Approval brings forward new treatment option with a novel mechanism for highly active relapsing multiple sclerosis in Switzerland - Approval based on extensive clinical development program capturing more than 10,000 ...
Darmstadt, Germany (ots/PRNewswire) - - MAVENCLAD® is now approved in 52 countries worldwide - Approval brings forward new treatment option with a novel mechanism for highly active relapsing multiple sclerosis in Switzerland - Approval based on extensive clinical development program capturing more than 10,000 ...
New Orleans (ots/PRNewswire) - Oral semaglutide 7 mg and 14 mg demonstrated superior HbA1c and body weight reductions compared to Januvia® (sitagliptin 100 mg). Non-inferiority for oral semaglutide 3 mg for HbA1c reductions at 26 weeks was not confirmed. Presented today at the Endocrine Society Annual Meeting in ...
Québec, Canada (ots) - GenePOC Inc., member of the Debiopharm Group, announces its third test to be cleared by the FDA, the GenePOC Strep A assay, to be used with the revogene(TM) device. About Group A Streptococcus (GAS) infection GAS is the most common bacterial etiology of pharyngitis accounting for 15 to 30% cases in children and 5 to 20% in adults[1]. In the ...
Paris and Zug, Switzerland (ots/PRNewswire) - Nordic Group, a pharmaceutical company focusing on the development and commercialisation of hospital and orphan products, and Primex Pharmaceuticals AG, an innovative global Anaesthesia pharmaceutical company, announced a strategic agreement today to launch OZALIN® in ...
Not intended for US, Canada and UK-based media Darmstadt, Germany and New York (ots/PRNewswire) - Merck and Pfizer Inc. (NYSE: PFE) today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by ...
Munich (ots/PRNewswire) - - In 2019, the Edoxaban Clinical Research Programme will deliver new evidence on LIXIANA® (edoxaban) use in clinical practice. EMIT-AF/VTE is one of the first sets of data to be presented - EMIT-AF/VTE is a large observational, multicentre, multinational study on edoxaban peri-procedural ...
- Late-Breaking Presentation of Final Results of Bempedoic Acid Pivotal Phase 3 CLEAR Wisdom at the American College of Cardiology (ACC) 2019 Scientific Sessions - Over 52-Weeks, Bempedoic Acid was Observed to be Safe, Well-Tolerated and Adverse Event Profile was Similar to that of Placebo[1] - Bempedoic Acid is an ...
Mont-Saint-Guibert, Belgium (ots/PRNewswire) - Nyxoah S.A., a healthtech company focusing on the development of innovative solutions and services for sleep related disorders, today announced that the company has received CE Mark approval for the Genio® system in Europe. The Genio® system is the world's first and ...
Munich (ots/PRNewswire) - - ELIMINATE-AF is the first set of data presented in 2019 from the Edoxaban Clinical Research Programme, which will deliver new evidence to support the use of edoxaban in clinical practice - Late-breaking data presented at EHRA 2019, the annual congress of the European Heart Rhythm ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for US, Canada and UK-based media - Collaboration agreement enables Merck access to Iktos AI technology across three drug discovery projects - Generative modelling AI technology enables rapid and cost-effective design of novel drugs - Agreement is part of Merck's R&D strategy to advance drug discovery with strategic ...
Oxford, England (ots/PRNewswire) - Oxford Nanopore has today made Flongle starter packs available to purchase https://store.nanoporetech.com/flongle.html, after initial testing in an early-access programme. Flongle introduces a new paradigm of smaller, on-demand DNA or RNA sequencing tests, with the potential to ...
Istanbul (ots/PRNewswire) - MLP Sagl?k Hizmetleri A.S. ("MLP Care") (BIST: MPARK), the leading private healthcare service provider in Turkey, today announces its financial results for the full year ended December 31, 2018. (TL millon) 2018 2017 Change Q4 Q4 Change 2018 2017 Revenue 3,132 2,576 21.6% 880 703 25.3% Comparable1 3,045 2,576 18.2% 840 703 19.5% Revenue Adj. EBITDA2 505 409 23.5% 152 126 20.3% Adj. Margin 16.1% ...